Objectives-To develop and apply an immunochemical approach to the study of drug-plasma protein conjugates derived from the anti-arthritic drug D-penicillamine (DP). Methods-An antiserum with specificity for protein-conjugated DP was raised in a rabbit. Plasma samples from patients receiving DP or from incubations of isolated normal plasma with DP were analysed for DP-derived conjugates by Western blotting using the anti-drug antibody.
band was detected in plasma samples from 15/16 patients with rheumatoid arthritis receiving DP but in none of 20 patients of similar disease status who had not taken DP. The positive band appeared in patients' plasma during the course of treatment with DP. It was seen under nonreducing but not reducing conditions indicating that the drug is disulphide linked to the protein. The drug-modified protein migrated to a position intermediate between the trailing edge of albumin and the leading edge of transferrin (both non-reduced) suggesting a molecular weight of between 66 and 77 kDa. Incubations of normal human plasma, but not purified albumin or transferrin, with low concentrations ofDP generated the same distinct band plus several less intense DP-positive bands. Conclusions-Drug-plasma protein conjugates derived from DP in vivo and in vitro can be detected immunochemically by the Western blot method. Theories of DP immunotoxicity have implicated antigenicity of the drug, but this is the first immunochemical demonstration of a potential DP-derived antigen in human plasma. The method we describe may have application to studies ofthe relationship between DP antigenicity and toxicity.
(Ann Rheum Dis 1994; 53: 256-260) D-penicillamine (DP) is a therapeutic agent in current use as a second line therapy for rheumatoid arthritis, and, by virtue of its metal-chelating and disulphide-reducing properties as a mainstay treatment for Wilson's disease, lead poisoning and cystinuria. The benefits of the drug in rheumatoid arthritis are severely curtailed by a high incidence of adverse reactions which necessitate withdrawal in up to 40% of patients.'2 Common side effects include skin rashes, fever and proteinuria. More rarely but more seriously, agranulocytosis, thrombocytopenia, and autoimmune disorders such as myasthenia gravis and systemic lupus erythematosus have been reported.' 2 The nature of these side effects, and their reported association with HLA DR33 has led to suggestions that adverse reactions to DP are mediated by the immune system,2-6 and the capacity of DP to conjugate by disulphide linkage to plasma proteins7 8 were electrophoretically transferred to nitrocellulose paper using a semi-dry blotter (Biometra). The blots were blocked for at least one hour in 2-5% casein in wash buffer (0 9% NaCl, 0-121% Tris, 0 04% thimerosal, pH 7-6). The blots were then incubated with one of the following antibody preparations diluted 1:500 or 1:1000 in 1% casein in wash buffer for 3 to 20 hours at room temperature on an orbital shaker: rabbit anti-DP antiserum, mouse monoclonal anti-human transferrin (Chemicon, London), mouse monoclonal antihuman albumin (Sigma), or goat anti-human albumin (Chemicon). After incubation with antibody the blots were washed once in wash buffer, once in detergent buffer (0-5% Triton X-100, 0-1% SDS in wash buffer), and twice again with wash buffer, and then incubated with either horse radish peroxidase (HRPO)-labelled goat anti-rabbit IgG (TAGO, Burlingame, CA, USA), HRPO-goat anti- 1) . This band was not seen in samples obtained from patients with rheumatoid arthritis who were not receiving the drug (fig 1) . This distinct DP-positive band was detected in plasma samples from 15/16 patients with rheumatoid arthritis who had started treatment with DP, in 0/20 patients with similar disease status but who had not received DP, and in 0/10 healthy volunteers who were receiving no medication.
When plasma samples were obtained from patients immediately before starting treatment with DP and then at monthly intervals during the treatment period, the DP-positive band was distinct at the first one-month time point and was retained at an equal intensity thereafter (fig 2) .
The single distinct DP-positive protein band, that was seen in plasma samples from patients taking the drug (fig 1, 2) , was not seen when blots were developed with control normal rabbit serum in place of the specific rabbit anti-DP antiserum (data not shown). The various high molecular weight, lightly staining bands that were seen in some blots developed with anti-DP (as in fig 1) also stained with normal rabbit serum and therefore represent non-specific binding of rabbit serum immunoglobulin or components of the HRPOlabelled second antibody to the separated human plasma proteins.
The DP-positive band was seen only when plasma samples were run under non-reducing conditions, that is, in the absence of dithiothreitol, indicating that the drug was bound to the protein by disulphide linkage. The DP band in non-reduced samples migrated to a position intermediate between the reduced molecular weight markers of 48-5 and 58 kDa (fig 1-4 Although close to the trailing edge of the albumin band the DP band was quite distinct from albumin since it appeared as a relatively narrow, horizontal band that was not stained by the anti-albumin antibodies, whereas the albumin band appeared as a broad band (also seen by amido black staining) with a down-curved trailing edge (fig 3) . In vitro incubations of DP with normal : plasma yielded a concentration-dependent increase in DP binding to proteins both quantitatively and qualitatively. At low concentrations of DP (0-06-0-13 mM) binding was detected only to a single protein band (fig 4) , migrating to a position corresponding to that id seen for the DP band seen in the patients'
,itis plasma samples (compare fig 4 with figs 1-3 ).
derived At higher concentrations of DP (0.5 mM and above) the above-mentioned DP band continued to increase in intensity, while a further two intensely staining DP-positive bands appeared, one at a position approximately half way between the 58 kDa and the 84 kDa reduced markers and one above the 116 kDa reduced marker (fig 4) . Each of these three distinct DP-induced bands and a number of other relatively weakly staining DP-induced bands ( fig 4) were seen under non-reducing but not reducing conditions, again indicating that the DP-derived determinants are disulphide conjugated to their protein targets. 15 but mples not with normal rabbit serum as control. It is uman also clearly drug-induced in vivo since it was tions, seen in plasma samples from 15/16 patients into with rheumatoid arthritis who were taking the rabbit drug but in none of 20 patients with anti-rheumatoid arthritis taking other medicines or in as before treatment with DP. When plasma n re-samples were taken from patients before and il gel. during treatment with DP, the conjugate was e DP absent before treatment, but after starting Anti-transferrin Anti-DP Anti-alburnin Figure 4 Western blot showing concentration-dependent generation of the DP-e protein conjugate after incubation of normal human plasma with a range of conce of the drug in vitro. The samples were electrophoresed and blotted as in jig 1 This is consistent with a simple spontaneous interaction of the drug (dimethylcysteine) with ed during free protein sulphydryl groups to generate a ent study disulphide-linked conjugate. At in vitro pearance concentrations of DP (0-25-4 Mm) conreatment, siderably higher than circulating levels reached rest to do in patients, further conjugates were detected, Western particularly two strong bands of higher mol-P-protein ecular weight than the single band seen at low result in drug concentrations in vitro. We are unable to to anti-guess the identity of these proteins or speculate on their significance. ein target
In conclusion, we have detected a single 7o but on discrete DP-derived conjugate on a protein of )bility in molecular weight 66-77 Kda in the plasma of .d trans-patients taking DP as treatment for rheumatoid nolecular arthritis. Because of the limited number of In earlier patients in this study, and because the DP conjugate could not be quantified, we cannot at the present time make any conclusions about its significance with regard to either the pharmacological or toxicological actions of DP. Nevertheless, since DP is known to induce immunotoxic reactions in a large proportion of patients, many of which appear to be of a hypersensitivity type, it is reasonable to suggest that this conjugate may be the causative antigen in these reactions. Of course, to consolidate this hypothesis it would be necessary to demonstrate antibodies in patients' sera directed against a DP-derived antigen. It may also be of interest to examine whether drugs related to DP, such as aurothiomalate, might generate potential antigens in an analogous fashion. Further studies to identify the DP binding protein, and quantitation of the conjugate formed in different individuals may throw some light on the mechanism and predictability of DP toxicity. 
